GeneDx is trading at $67.41, down 4.01%, with no clear company-specific explanation for the October 16 decline in available reporting.

  • The latest company news found was an October 2 release about genomic newborn screening.
  • October 16 coverage reported a CEO share sale from September 16, not a new transaction today.
  • Supplied market indicators are mixed and do not establish a clear broad-market explanation for the move.